Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech Philadelphia, PA, August 5, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic...
-
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
-
NodThera Ltd (“NodThera” or the “Company”) NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors ...
-
Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...
-
NodThera Ltd (“NodThera” or the “Company”) NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor NT-0796 demonstrates...
-
NodThera Ltd (“NodThera” or the “Company”) NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors Oral, small molecule, clinical candidates NT-0249...